Loss of CD26 protease activity in recipient mice during hematopoietic stem cell transplantation results in improved transplant efficiency

Dipeptidyl peptidase IV (DPPIV/CD26) inhibition does not improve engraftment of unfractionated syngeneic or allogeneic bone marrow after nonmyeloablative conditioning

(2011) Elisabeth Schwaiger et al.   EXPERIMENTAL HEMATOLOGY

DPP-4 inhibitors: What may be the clinical differentiators?

(2010) John Gerich   DIABETES RESEARCH AND CLINICAL PRACTICE

Effective mobilization of hematopoietic progenitor cells in G-CSF mobilization defective CD26−/− mice through AMD3100-induced disruption of the CXCL12-CXCR4 axis

(2010) Laura A. Paganessi et al.   EXPERIMENTAL HEMATOLOGY

Dipeptidyl Peptidase-4 Inhibitors for the Treatment of Type 2 Diabetes Mellitus

(2010) Joshua J Neumiller et al.   PHARMACOTHERAPY

HLA-Haploidentical Stem Cell Transplantation for Hematologic Malignancies

(2009) Ephraim J. Fuchs et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Emerging Drug Candidates of Dipeptidyl Peptidase IV (DPP IV) Inhibitor Class for the Treatment of Type 2 Diabetes

(2009) Rajesh Gupta et al.   CURRENT DRUG TARGETS

Mesenchymal stem cells from the Wharton's jelly of umbilical cord segments provide stromal support for the maintenance of cord blood hematopoietic stem cells during long-term ex vivo culture

(2008) Tiki Bakhshi et al.   TRANSFUSION